BALTIMORE, Nov. 21,
2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc.
(NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative
pre-clinical-stage pharmaceutical company, today announced it will
host a shareholder update call on Tuesday,
December 5, 2023 at 11:30 a.m.
Eastern Time.
Dr. Adam Kaplin, MD, PhD,
President and Chief Scientific Officer of MIRA, and Erez Aminov, Chief Executive Officer of MIRA,
will discuss the Company's recent announcement regarding its
exclusive licensing agreement to develop and commercialize
Ketamir-2, a novel oral ketamine analog designed to revolutionize
the landscape of depressive disorder treatments.
Shareholder Update
Call
|
Date:
|
Friday, December 5,
2023
|
Time:
|
11:30 a.m. Eastern
Time
|
Dial-in (U.S.):
|
1-877-269-7751
|
International
Dial-in:
|
1-201-389-0908
|
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1645560&tp_key=181adb3815
|
A telephone replay will be available approximately three hours
after the call and will run through Friday,
January 5, 2024, by dialing 1-844-512-2921 from the U.S., or
1-412-317-6671 from international locations, and entering replay
pin number: 13742854. The replay can also be viewed through the
webinar webcast link above.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company developing an
unscheduled novel synthetic THC analog. This novel compound is
currently under investigation for treating adult patients suffering
from anxiety and cognitive decline, often associated with
early-stage dementia. MIRA1a, if approved by the FDA, could mark a
significant advancement in addressing various neuropsychiatric,
inflammatory, and neurologic diseases and disorders. Based on
pre-clinical and animal studies conducted by the Company, the
Company believes that MIRA1a may enhance the therapeutic potential
for treating anxiety, cognitive decline, and neuropathic pain
without the side effects of plant-based THC. Furthermore, the
Company's studies show that MIRA1a may counteract the adverse
cognitive effects often seen with THC, thereby potentially
unmasking previously unseen positive therapeutic effects, such as
cognitive performance enhancement.
The U.S. Drug Enforcement Administration (DEA)'s scientific
review of MIRA1a concluded that MIRA1a would not be considered a
controlled substance or listed chemical under the Controlled
Substances Act (CSA) and its governing regulations or require
scheduling during development.
Additional information about the Company is available
at: www.mirapharmaceuticals.com.
Forward-Looking Statements
This press release may contain forward-looking statements about
MIRA Pharmaceuticals, Inc. ("MIRA," "we," "us," or "our"). In
some cases, you can identify forward-looking statements by
terminology such as "anticipate,' "believe," "contemplate,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will" or
"would," or the negative of these terms or other comparable
terminology. These forward-looking statements are
subject to numerous risks and uncertainties, many of which are
beyond our control, including risks and uncertainties regarding our
ability to develop and obtain regulatory approval for our product
candidates, Ketamir-2 and MIRA1a. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, which may cause our actual results, levels of
activity, performance or achievements of and those of our industry
to be materially different from any future results, levels of
activity, performance or achievements expressed or implied by these
forward-looking statements. Some of these risks and
uncertainties are identified in our Registration Statement on Form
S-1 filed with the SEC (File No. 333-273024) and in our other
filings with the SEC, which are available at www.sec.gov. You
should not place undue reliance on any forward-looking
statement. We undertake no obligation to update or revise
publicly any of the forward-looking statements after the date
hereof to conform the statements to actual results or changed
expectations except as required by law.
General Note
This press release discusses product candidates that are in
early stage pre-clinical development and have not yet been approved
for marketing by the U.S. Food and Drug Administration. No
representations are made as to the safety or effectiveness of these
product candidates for the uses for which they are being studied.
There is no assurance that either product candidate will proceed
through development or will receive FDA approval for marketing.
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-to-host-shareholder-update-call-on-tuesday-december-5-2023-at-1130-am-eastern-time-301994972.html
SOURCE MIRA Pharmaceuticals, Inc.